All In Biotech

NDA 020648 · Bausch

Diastat Acudial

Diazepam · Rectal · Benzodiazepine

Orphan

Last checked: Nov 19, 2026Latest source record: Jul 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Jul 29, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

118

16 Phase 3, 6 recruiting

FAERS reports

90,054

76,639 serious, 20,859 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including diazepam rectal gel, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...

What it is approved for

From the label in effect Jan 4, 2024.

INDICATIONS AND USAGE Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

7 products under this application
  • DIASTAT ACUDIAL · DIAZEPAM 20MG/4ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB
  • DIASTAT · DIAZEPAM 15MG/3ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
  • DIASTAT · DIAZEPAM 5MG/ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
  • DIASTAT ACUDIAL · DIAZEPAM 10MG/2ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB
  • DIASTAT · DIAZEPAM 20MG/4ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
  • DIASTAT · DIAZEPAM 10MG/2ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · GEL, RECTAL · Discontinued
  • DIASTAT · DIAZEPAM 2.5MG/0.5ML (5MG/ML) · GEL, RECTAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.

All 118 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • toxicity to various agents9,224
  • drug abuse6,198
  • drug ineffective5,045
  • nausea4,204
  • drug interaction3,886
  • completed suicide3,880
  • fatigue3,807
  • somnolence3,636
  • off label use3,550
  • anxiety3,387
  • death3,387
  • headache3,270

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,140
20051,344
20061,170
20071,233
20081,797
20091,793
20102,345
20112,776
20123,252
20133,740
20143,766
20154,657
20165,306
20175,529
20186,524
20197,145
20206,726
20215,695
20224,983
20234,864
20245,151
20255,144
20263,963

Recalls

1 FDA enforcement reports for this application.

  • Jul 10, 2018 · Class III · Terminated

    Labeling: Incorrect or Missing Lot and/or Exp Date: Product distributed without a lot number or expiration date on the outer carton.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,534 on PubMed

Sponsor: Bausch · Also marketed as Diastat

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.